Prevention of HIV transmission in the UK: what is the role of male circumcision?

Abigail MacDonald, Joanna Humphreys, Harold W Jaffe

These two scenarios raise the question of whether male circumcision should be used in the UK as a means to decrease HIV transmission. Lack of circumcision has long been recognised as a risk factor for HIV acquisition in heterosexual men. This makes biological sense because superficial Langerhans cells, which express HIV-1 receptors, are more prevalent in the penis. In addition, decreased keratinisation of the foreskin increases susceptibility to minor trauma during intercourse, potentially aiding the passage of HIV. Finally, ulcerative sexually transmitted infections, found more commonly in uncircumcised men, are associated with increased rates of HIV transmission.

The biological plausibility of adult male circumcision to reduce HIV transmission has now been shown to have clinical relevance in three recent large randomised controlled trials conducted in sub-Saharan Africa, in which male circumcision reduced the rate of female-to-male HIV transmission by at least 50%. Overall, there was little evidence of increased risk-taking behaviour in circumcised men. We examine whether the results of the African trials are relevant in the UK.

THE ISSUE FOR THE UK

The yearly number of new HIV diagnoses in the UK has increased by 157% since 1997. Of the new diagnoses reported in 2006, 12% were in black African men, most of whom were thought to have been infected heterosexually in Africa, whereas 36% were in men who have sex with men (MSM). Indeed, 2006 saw the greatest yearly number of newly diagnosed HIV infections in MSM since the start of the epidemic. New prevention strategies for these groups are urgently needed.

SCENARIO 1

Based on the biological rationale and clinical trial data, the World Health Organization (WHO) has recently recommended that “countries with high prevalence, generalised heterosexual HIV epidemics that currently have low rates of male circumcision consider urgently scaling up access to male circumcision services”. Although the hypothetical patient described in scenario 1 resides in the UK, we believe that the WHO guidelines would apply to him and argue that it would be appropriate to offer circumcision to him.

Current National Health Service (NHS) guidelines, however, appear to pertain mainly to paediatric circumcision and generally discourage the procedure. For example, NHS Choices notes that “In the UK, circumcision is only carried out on the NHS in cases where it is medically necessary. It is usually performed as a last resort when other types of treatment have been unsuccessful.” A similar stance is taken by the British United Provident Association, a major source of private healthcare insurance in the UK (personal communication with Actuarial and Medical Risk Analyst, British United Provident Association, 15 August 2007).

SCENARIO 2

In their guidelines, WHO made no specific recommendation regarding circumcision for MSM. The US Centers for Disease Control and Prevention also reached no conclusion on this issue for MSM in the United States. Simple extrapolation from the data on African heterosexual men is clearly inappropriate because MSM engage in a variety of other sexual practices, including anal and oral intercourse, which can be either insertive or receptive. Of these practices, those involving anal sex, particularly receptive anal sex, are most likely to transmit HIV.
Potentially, the circumcision of MSM who engage in insertive anal intercourse might protect them from infection from receptive partners or, if they are already infected, it might protect their receptive partners from infection. The results of studies on circumcision status and the risk of HIV in MSM are, however, very limited and conflicting. Both a cross-sectional and a prospective study of MSM in the United States found an increased prevalence of HIV in uncircumcised men. Neither study was designed to determine the specific sexual practice by which these men became infected. A more recent cross-sectional study of black and Latino MSM in three US cities found no evidence that circumcision was protective in men who engaged in unprotected insertive anal sex. A prospective Australian trial study also reported no relationship between circumcision status and HIV seroconversion in either the entire MSM study population or those men who denied practising receptive anal intercourse.

Given the lack of data, we would also be unable to make a specific recommendation regarding the patient presented in scenario 2.

**WHAT SHOULD BE DONE?**

First, we believe the NHS and, potentially, private insurers, should examine their existing policies for adult male circumcision. For recent male émigrés from high HIV-prevalence countries in sub-Saharan Africa whose female partners are also from these countries, we believe circumcision should be made available in accordance with WHO recommendations.

Second, to determine definitively whether circumcision could play a role in HIV prevention for MSM, a clinical trial is needed. Major determinants of the feasibility of such a trial would be HIV incidence in the participants and current circumcision rates.

The Health Protection Agency estimated that among MSM attending sentinel genitourinary medicine clinics in London during 2006, HIV incidence was 2.6%, a rate generally similar to that seen in the non-circumcised control groups enrolled in the African clinical trials. Whereas these findings might suggest that an MSM trial could be performed with similar numbers of persons as in the African studies, an estimate of HIV incidence for men engaging in unprotected insertive anal sex would be needed for a sample size calculation.

The relatively low circumcision rates of UK men would also facilitate circumcision trials. The National Survey of Sexual Attitudes and Lifestyle of 2001 found that only 15.8% of UK men between the ages of 16 and 44 years had been circumcised.

Of course, such trials would not be ethical without extensive risk-reduction counselling for participants and would not be possible without the willing participation of at-risk MSM. Pilot studies would be needed to determine the likely participation rates. A recent survey of uncircumcised MSM performed in the United States indicated that more than half would be willing to be circumcised if this were shown to reduce the risk of HIV infection.

The primary study endpoint would be the effect of circumcision on HIV incidence for men engaging in unprotected insertive anal sex. We believe this study could be conducted in UK genitourinary medicine clinics. If additional trial sites were needed to recruit a sufficiently large number of participants, they could be identified in countries with a concentrated MSM HIV epidemic and low circumcision rates; eg, in Scandinavia or Latin America.

A second study might also be considered to examine the effect of circumcising previously infected MSM on the risk of infecting persons who are their receptive partners in unprotected anal sex. An analogous study of circumcision for HIV-infected Ugandan men to reduce the risk of infecting their female partners was, however, stopped prematurely. Preliminary data had shown no evidence of decreased transmission from circumcised men and suggested that men who resumed sexual activity before complete wound healing might pose an increased risk transmission risk to their partners. Further consultation would be needed to decide if this MSM study should be carried out in the UK.

The UK has the opportunity to lead in revising its male circumcision guidelines in accordance with new African data and to develop data upon which to consider new circumcision strategies for MSM. We believe these opportunities are important and should not be missed.

**REFERENCES**


